Axon Enterprise, Inc.

Axon Enterprise maintains a dedicated Israel office with a Country Manager based in Tel Aviv and held its first Axon Tech Summit in Israel in 2025. The Israel Police acquired approximately 1,800 Taser X26P devices between 2016 and 2023 via public tender. The Israel Border Police uses Tasers in operations in the occupied West Bank against Palestinians. The Israeli military deployed Taser guns to special units starting in 2009, and the Israeli Navy used Tasers during attacks on Freedom Flotilla activists attempting to break the siege on Gaza. The Israel Prison Service and Population and Immigration Authority also use Axon Tasers. AFSC Investigate documents these sales as direct facilitation of occupation enforcement. In November 2025, Axon acquired Israeli AI startup Carbyne for $625 million, deepening its operational ties to Israel.

Taser devices manufactured by Axon Enterprise are disproportionately deployed against Black individuals, who are over four times more likely to be subjected to Taser use than white individuals. When Taser encounters turn fatal, Black people comprise 32% of deaths despite being 14% of the US population. Research from Keele University, UCL, and the University of Exeter (2023) found structural racism drives this disparity — policing concentrates in deprived areas where Black and ethnic minority populations disproportionately live. The ACLU has documented cases of Taser use on compliant Black individuals. Multiple DOJ consent decrees (Ferguson, Seattle, others) have found patterns of racially biased force, with Tasers as a primary tool. While Axon does not directly control deployment, it manufactures and aggressively markets the weapon that serves as the primary instrument of racially disparate use of force across US law enforcement. ICE purchased $2.6 million in Axon Tasers (2020-2021) and used them during deportation flights.

Axon Enterprise manufactures and sells Taser conducted energy devices responsible for over 1,000 deaths in the United States since 2000, according to Reuters investigations. The company faced at least 442 lawsuits from families of Taser-related deaths as of 2017, with many cases alleging the devices were marketed as non-lethal despite known cardiac risks. Axon (then TASER International) historically fought liability aggressively, spending millions to defend product claims while people continued to die from Taser-induced cardiac arrest. In 2025, the company began developing covert Taser weapons marketed to corporate executives, extending the weaponization of its core product line into private civilian markets. The product carries inherent lethal risk that the company has systematically downplayed for decades.